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Abstract: Background:  Venous leg ulcers (VLUs) are the commonest cause of leg ulceration,
affecting 1 in 100 adults.  There is a significant health burden associated with VLUs - it
is estimated that the cost of treatment for one ulcer is up to £1300 per year in the NHS.
The mainstay of treatment is with graduated compression bandaging, however
treatment is often prolonged and up to one quarter of venous leg ulcers do not heal
despite standard care.  Two previous trials have suggested that low-dose aspirin, as
an adjunct to standard care, may hasten healing, but these trials were small and of
poor quality.  Aspirin is an inexpensive, widely used medication but its safety and
efficacy in the treatment of VLUs remains to be established.
Methods / design: AVURT is a phase II randomised double blind, parallel-group,
placebo-controlled efficacy trial.  The primary objective is to examine whether aspirin,
in addition to standard care, is effective in patients with chronic VLUs (i.e. over 6 weeks
in duration or a history of VLU).   Secondary objectives include feasibility and safety of
aspirin in this population.  A target of 100 participants, identified from community leg
ulcer clinics and hospital clinics, will be randomised to receive either 300mg of aspirin
once daily or placebo.  All participants will receive standard care with compression
therapy.  The primary outcome will be time to healing of the reference ulcer.   Follow-
up will occur for a maximum of 27 weeks.  The primary analysis will use a Cox
proportional hazards model to compare time to healing using the principles of intention
to treat.  Secondary outcomes will include ulcer size, pain evaluation, compliance and
adverse events.
Discussion:  The AVURT trial will investigate the efficacy and safety of aspirin as a
treatment for VLU and will inform on the feasibility of proceeding to a larger phase III
study.  This study will address the paucity of information currently available regarding
aspirin therapy to treat VLU.
Trial registration:  The study is registered on a public database with clinicaltrials.gov
(NCT02333123; registered on 5th November 2014).
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Abstract 
Background:  Venous leg ulcers (VLUs) are the commonest cause of leg 
ulceration, affecting 1 in 100 adults.  There is a significant health burden 
associated with VLUs – it is estimated that the cost of treatment for one ulcer is 
up to £1300 per year in the NHS.  The mainstay of treatment is with graduated 
compression bandaging, however treatment is often prolonged and up to one 
quarter of venous leg ulcers do not heal despite standard care.  Two previous 
trials have suggested that low-dose aspirin, as an adjunct to standard care, may 
hasten healing, but these trials were small and of poor quality.  Aspirin is an 
inexpensive, widely used medication but its safety and efficacy in the treatment 
of VLUs remains to be established.   
Methods / design: AVURT is a phase II randomised double blind, parallel-group, 
placebo-controlled efficacy trial.  The primary objective is to examine whether 
aspirin, in addition to standard care, is effective in patients with chronic VLUs 
(i.e. over 6 weeks in duration or a history of VLU).   Secondary objectives include 
feasibility and safety of aspirin in this population.  A target of 100 participants, 
identified from community leg ulcer clinics and hospital clinics, will be 
randomised to receive either 300mg of aspirin once daily or placebo.  All 
participants will receive standard care with compression therapy.  The primary 
outcome will be time to healing of the reference ulcer.   Follow-up will occur for a 
maximum of 27 weeks.  The primary analysis will use a Cox proportional hazards 
model to compare time to healing using the principles of intention to treat.  
Secondary outcomes will include ulcer size, pain evaluation, compliance and 
adverse events.   
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Discussion:  The AVURT trial will investigate the efficacy and safety of aspirin as a 
treatment for VLU and will inform on the feasibility of proceeding to a larger 
phase III study.  This study will address the paucity of information currently 
available regarding aspirin therapy to treat VLU. 
Trial registration:  The study is registered on a public database with 
clinicaltrials.gov (NCT02333123; registered on 5th November 2014). 
 
Key words: Leg ulcer, venous ulcer, wound healing, aspirin, compression therapy 
 
Background 
Venous leg ulcers (VLUs) are wounds of the lower limb caused by a diseased 
venous system, typically occurring in the gaiter area of the leg.  VLUs represent 
the most common cause of leg ulceration, with a lifetime prevalence of 1-3% in 
UK adults and accounting for around 85% of all lower limb ulcers 1.   
Many VLUs take over 6 months to heal; one large study demonstrated a median 
time to ulcer healing of 99 days with two-layer compression therapy 2.  In 
addition, more than a quarter fail to heal completely 3 and the 12-month 
recurrence rate of healed VLUs may be up to 28% 4 5.  Patients with 
longstanding, large ulcers, or who have a prior history of ulceration, are 
particularly resistant to healing 6 7.  VLUs impair quality of life; they are open 
wounds, which can be large, are often painful, frequently become infected and 
leak exudate.  Compression bandaging is an effective treatment 8 but requires the 
use of sometimes bulky bandages alongside the need for regular clinic visits.  
Health-related quality of life (QoL) is decreased in patients with VLUs, which can 
incur significant psychological morbidity9, and successful treatment has been 
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shown to significantly improve QoL 10.   VLUs represent a significant health 
economic burden, costing up to £1300 to treat one VLU episode for a year in the 
UK 11.  There is therefore an unmet need for a more cost-effective and clinically 
effective treatment for VLUs. 
 
Pathophysiology of venous leg ulcers 
In a healthy individual, flow of venous blood back to the heart occurs via the 
superficial venous system through the deep venous system, using the calf muscle 
pump and the venous valves to facilitate this flow against gravity.  Resting 
hydrostatic venous pressure in the lower limb is 80mmHg in the standing 
position, with no pressure gradient.  When exercising, pressure in the deep 
venous system exceeds 80mmHg, due to contraction of the calf muscles, forcing 
blood flow towards the heart.  Valves in the superficial and perforator venous 
systems close to prevent retrograde flow.  When the leg muscles relax again, 
pressure in the deep system falls below 80mmHg, allowing blood to flow from 
the superficial system to the deep system through patent valves.  Any 
dysfunction along this pathway may contribute to the development of venous 
ulceration. 
VLUs most commonly result from impaired venous return due to calf muscle 
pump failure, usually as a result of obstruction or valve dysfunction in the 
superficial, deep or perforator venous system in the leg (primary venous 
disease).  VLU may also occur following a deep vein thrombosis or trauma 
(secondary venous disease).  Other important factors include obesity and 
immobility. 
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Pathological maladaptation underlying VLU include structural changes in vessel 
walls such as intimal hyperplasia, increased collagen content in areas of 
hypertrophy, as well as reduced smooth muscle cells and extracellular matrix 12.  
These changes are likely triggered by inflammation and contribute to loss of 
venous tone and, ultimately, venous reflux and hypertension.   These structural 
changes are also accompanied by cellular changes in the wound and wound bed - 
increased proteolytic activity, platelet aggregation and infiltration of leucocytes 
into the dermis, causing dermal fibrosis and leading to cutaneous changes such 
as lipodermatosclerosis, haemosiderin deposition and ulceration.  
Haemodynamic changes resulting from venous hypertension also affect the 
microcirculation, promoting interstitial oedema and capillary leakage. This 
combination of inflammatory activities may cause the VLU to heal slowly, or not 
at all.  Targeting and reversing these pathophysiological pathways is the focus of 
adjunctive drug treatment. 
 
Current treatment of venous leg ulcers  
Careful and regular clinical assessment should be the first step in the 
management of venous ulceration and should ideally be performed in a 
specialised venous ulcer clinic.  All patients should have a venous Duplex scan to 
assess for treatable venous disease.  Ulcer area and characteristics should be 
monitored over time, as the changing nature of an ulcer (depth, area, base, ulcer 
edge) can indicate progression of disease or healing.  Bacteriological swabs and 
antibiotics should only be used in cases of proven clinical infection and a biopsy 
may be considered in cases of atypical or non-healing ulceration.  Simple 
dressings, meticulous wound care and judicious sharp debridement should be 
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undertaken by experienced practitioners.  All patients with VLUs should have 
ankle brachial pressure index (ABPI) performed prior to the instigation of 
treatment to exclude arterial disease and should have cardiovascular risk factors 
addressed in the presence of an abnormal ABPI, in addition to referral to a 
vascular surgeon.  Compression therapy should be instigated and undertaken by 
an appropriately trained professional.  According to SIGN guidelines, patients 
with chronic non-healing VLU and concomitant superficial venous reflux should 
be referred for consideration of surgery to prevent recurrence 13. 
 
Compression therapy 
The standard treatment of VLUs is multi-layered compression bandaging (aiming 
for a pressure of 40mmHg at the ankle 14 with the aim to reduce venous 
hypertension, improve calf muscle function and create a wound environment 
that encourages healing whilst reducing tissue maceration and excessive oedema 
and moisture.   Compression is recommended as first-line treatment for VLU in 
major UK guidelines 13. 
The gold standard is 4-layer multi-component compression therapy 15, however 
this is often considered unsightly and uncomfortable, due to the bulky nature of 
the bandages, and may restrict movement at the ankle, making it difficult to wear 
shoes.  In addition, poor application technique may reduce the effectiveness of 
compression and the negative physical and social impact of compression 
stockings may lead to ambivalence about their effectiveness and subsequent 
non-compliance16.   2-layer compression stockings are an alternative to 4-layer 
bandaging and a recent randomised trial has demonstrated a reduction in ulcer 
recurrence with the 2-layer approach17 2.  Various single-layer hosiery are also 
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available, however these do not meet the 40mmHg targeted compression 
pressure.   
 
Topical therapy 
Topical therapies have been used for VLUs (including silver-containing 
antibiotics, zinc oxide and other topical antimicrobials or impregnated 
dressings) although there is no reliable evidence to suggest that complex wound 
dressings are better than simple non-adherent dressings 18.  Topical local 
anaesthetic creams may help bring symptomatic relief when the ulcers are 
painful. 
   
Adjunctive drug treatment 
Various drug adjuncts to compression have also been investigated, with a recent 
Cochrane Review demonstrating that pentoxyfilline (a vasodilator that decreases 
blood viscosity, modifies leucocyte activity and has some anti-platelet effects) is 
effective in improving wound healing when used with, and possibly without, 4-
layer compression 19.  However, vasodilators such as pentoxyfilline are not 
routinely prescribed in the NHS and may have intolerable adverse events, 
including potentially life-threatening side-effects such as haematemesis, 
gastrointestinal haemorrhage and thrombocytopenia 20.  There is insufficient 
evidence to recommend the use of other adjunctive drugs, including venoactive 
drugs that increase venous tone via mechanisms that remain largely unclear. 
 
Aspirin 
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Aspirin is a cyclooxygenase inhibitor that irreversibly reduces prostaglandin-2 
and thromboxane A2, which are involved in inflammation and platelet 
aggregation21.  It is inexpensive, widely used and readily available.  The 
mechanism by which aspirin may hasten healing of VLU is unclear but may be 
associated with a reduction of inflammation, or its effect on the microvascular 
circulation, including platelet activation.  In one study investigating the 
haemostatic effects of aspirin in patients with VLU, the investigators 
demonstrated that participants were found to have increased levels of fibrinogen 
and shortened coagulation rate, when compared to age- and sex-matched 
controls and that treatment with aspirin caused prolongation of the coagulation 
rate, which increased the rate of ulcer healing 22. 
There have been two small randomised trials to date that have investigated the 
use of aspirin (300mg) in VLUs, however the quality of evidence presented was 
low and more robust studies are required to confirm their findings.  An 
additional file outlines the previous studies investigating aspirin in VLU [see 
Additional File 1]. 
The first study was carried out in 1994 and demonstrated that 38% more 
patients healed in the treatment group (aspirin plus compression) than in the 
control group (placebo plus compression)23, however no patients healed within 
4 months in the control group, which is surprising, given that the median time to 
healing with compression alone is around 3 months 15.  Although it provides 
some limited data about the potential use of aspirin therapy, the sample size of 
only 20 patients is insufficient to draw meaningful conclusions.  In addition, 
patients were only followed up for 4 months.  
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Over a decade later, a Spanish group conducted a small randomised pilot trial 
(n=51 patients) of aspirin and compression, demonstrating that aspirin reduced 
the average time to healing but did not influence the rate of healing and had no 
effect on the rate of ulcer recurrence.  In addition, after multivariate analysis was 
performed, aspirin was not demonstrated to be an independent predictor of 
healing 24 with only initial ulcer size at study entry remaining independently 
associated with rate of healing .  Moreover, no information was presented 
regarding the placebo and there is uncertainty around the effect estimates.  The 
quality of evidence that aspirin hastens healing of VLUs is therefore low and 
needs addressing through more robust studies.   
In addition to the AVURT trial, there are two ongoing randomised trials 
investigating the use of aspirin in VLU.  ASPiVLU (ASPirin in Venous Leg Ulcer 
healing, ACTRN12614000293662) will investigate the use of 300mg aspirin, in 
addition to standard 3-layer compression therapy, with the primary endpoint as 
the time to complete ulcer healing at or before 12 weeks from randomisation.  
Aspirin4VLU (Low Dose Aspirin for Venous Leg Ulceration, NCT02158806) will 
investigate 150mg aspirin, in addition to routine care, on time to complete 
healing of the reference ulcer.  In addition to the trials reporting individually, 
data from AVURT, ASPiVLU and Aspirin4VLU will be combined in order to carry 
out an individual patient data (IPD) meta-analysis.  Any other relevant trials such 
as the two earlier trials will also be considered for inclusion. 
 
Other options: surgery and minimally invasive intervention 
Varicose vein surgery for VLUs has not been shown to influence the time to VLU 
healing, however may decrease the rate and severity of recurrence 4, 25.  
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Minimally invasive techniques such as radiofrequency ablation, foam 
sclerotherapy and endovascular laser ablation have largely replaced traditional 
open surgical techniques in the treatment of varicose veins, where possible.  
There have been no large-scale randomised trials investigating the superiority of 
one technique over another when treating VLUs, although recent studies suggest 
some benefit from radiofrequency ablation to assist VLU healing 26.  However, a 
large multi-centre randomised trial is currently underway (EVRA – Early Venous 
Reflux Ablation ulcer trial), aiming to assess the influence of early endovenous 
treatment of superficial venous reflux in patients with VLUs, compared to 
standard compression therapy (NIHR HTA 11/129/197; ISRCTN02335796).  
 
Other options: cell-based therapy, skin grafts and acellular products 
Research on novel treatments with cell-based therapy is currently in progress, 
with promising results from phase II and phase III trials investigating the use of 
allogenic cells, either applied topically or via injection onto areas of ulceration 27 
28 as well as growth factors 29. However such therapies are expensive, may be 
associated with significant side effects and are unlikely to become widely 
available in the near future.  Accellular products, such as porcine mucosa, have 
been trialled to assist VLU healing, with promising results noted in one study 30.  
A recent Cochrane Review of skin grafting for VLU (including autografts, 
allografts, xenografts and bioengineered artificial skin grafts) demonstrated that 
bilayer tissue-engineered skin replacement, used with compression, was the only 
skin grafting technique that may increase the rate of VLU healing 31, but data are 
very limited in this area. 
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The need for AVURT – a randomised, placebo-controlled efficacy study 
Whilst there have been two small trials to date that have investigated the use of 
aspirin in the treatment of VLUs, the quality of the evidence presented is low.  
Given the significant health burden represented by VLUs, and the challenges in 
treating the disease, there is a need to identify effective, inexpensive, safe and 
widely available treatments that patients may tolerate.  The Aspirin for Venous 
Ulcers: Randomised Trial (AVURT) seeks to investigate the effect of aspirin on 
time to healing of VLU, to examine safety issues in this cohort of patients and to 
inform on the feasibility of proceeding from a phase II trial to an efficacy and 
effectiveness (phase III) trial.  If a simple, cheap and well tolerated medication, 
such as aspirin, were to result in a reduction in time to healing, this would 
impact on patient management, resource use and the potential impact on the 
population is substantial, given that aspirin is widely available.  Meta-analyses 
have demonstrated that low-dose aspirin increases the risk of major bleeding 
compared to placebo 32, 33 ,  however the absolute increase is modest and there is 
no evidence that decreasing the dose will reduce the risks of side effects 34.   The 
study will also provide the opportunity to systematically review the safety 
profile of aspirin in this population of patients, as well as assess the 
generalisability of the medication by studying the number of patients with VLUs 
who are currently taking aspirin or other anti-platelet medications.  
 
Methods / design 
Trial design 
The AVURT trial is designed to inform the feasibility of a larger, confirmatory 
study of aspirin therapy for VLU.  AVURT is a phase II randomised, double blind, 
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parallel-group, placebo-controlled study to provide evidence regarding the 
efficacy and safety of aspirin (at a dose of 300mg once daily), in addition to 
standard care in patients with chronic VLUs.  A chronic VLU is defined as any 
break in the skin that has either: a) been present for more than six weeks, or b) 
occurred in a person with a history of venous leg ulceration.  Ulcers will be 
considered venous if no other aetiology is clinically suspected.  The ulcer must be 
venous in appearance (i.e. moist, shallow and irregular of appearance) and lie 
wholly or partially within the gaiter area of the leg.   Potential participants will 
be identified from hospital outpatient clinics or community leg ulcer clinics, 
where they usually receive treatment for VLU.  An additional file shows the 
schematic of the AVURT trial design [see Additional File 2].  All participants will 
continue to receive ‘standard care’ according to an evidence-based standardised 
approach to the management of VLU, as per SIGN guidelines 13 with multi-
component compression therapy aiming to deliver 40mmHg at the ankle.  The 
type of dressing used will be at the discretion of the healthcare professional 
managing the patient and will be documented in the participant case report form 
(CRF).   
Aspirin will be provided as a 300mg capsule identical in weight, colour and size 
to the matched placebo capsules.  Placebo capsules will contain a lactose and 
magnesium stearate blend.  Capsules will be packaged into child-resistant 
tamper evident bottles sufficient in size to hold 190 doses for the participant to 
complete 24 weeks treatment. 
 
Ethical approval 
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Full ethical approval has been granted by the NRES East Midlands – Nottingham 
2 ethics committee (reference 14/EM/1305).  
 
Screening, eligibility and patient pathway 
Screening will be conducted by research nurses, who will also identify potential 
participants, gain informed consent and conduct a baseline assessment.  Patients 
will be recruited from hospital and community based ulcer clinics, and through 
liaison with GPs, community nurses and hospital staff.  Eligibility will be 
confirmed by a doctor.  The participant will continue with regular (usually 
weekly or two-weekly) visits to the usual place of ulcer care, where the research 
or treating nurse will assess the components involved in the study.  An 
additional file shows a summary of AVURT assessments [see Additional File 3]. 
 
Inclusion criteria 
Inclusion criteria are: 
 Patients with at least one chronic venous leg ulcer (if more than one ulcer, 
the largest ulcer will be chosen as the reference ulcer for the purposes of 
the trial) 
 Ulcer area >1cm2 
 Ankle brachial pressure index (ABPI) ≥0.8 taken within the previous 
three months, or 
 If the ABPI is incompressible, other forms of clinical assessment must 
exclude peripheral arterial disease (peripheral pulse examination, toe 
pressure, duplex ultrasound, clinical judgement) 
 Age over 18 years (no upper age limit) 
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 Informed consent 
 
Exclusion criteria 
The exclusion criteria are: 
 Unable to provide consent 
 Unwilling to provide consent 
 Foot ulcer (i.e. below the ankle) 
 Leg ulcer of non-venous aetiology 
 Ankle-brachial pressure index (ABPI) <0.8 or, where ABPI is not 
compressible, PAD cannot be excluded by other assessments 
 Regular concomitant aspirin 
 Previous intolerance or contraindication to aspirin use (according to 
prescriber’s clinical judgement) 
 Prohibited medication: probenecid; oral anticoagulants including 
coumarins (warfarin, acenocoumarol) and phenindione; dabigatran; 
rivaroxaban; apixiban; heparin; clopidogrel; dipyridamole; 
sulfinpyrazone and iloprost 
 Known lactose intolerance 
 Pregnant / lactating women 
 Male or pre-menopausal female participants of child-bearing potential* 
unwilling to use an effective method of birth control (either hormonal in 
the form of the contraceptive pill or barrier method of birth control 
accompanied by the use of a proprietary spermicidal foam/gel or film ; or 
agreement of true abstinence (i.e. withdrawal, calendar, ovulation, 
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symptothermal and post ovulation are not acceptable methods) from time 
consent is signed until 6 weeks after the last dose of IMP 
 Already participating in another study investigating leg ulcer therapy 
 Previously been recruited into this trial 
 Another reason that excludes them from participating within this trial 
(decision made according to the nurses’ or prescribers’ clinical judgment)  
 
*Subjects are only considered not of child bearing potential if they are surgically 
sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or 
bilateral oophorectomy) or they are postmenopausal. 
 
There will be no exceptions (waivers) to eligibility criteria.  Participants will be 
considered eligible if they meet all of the inclusion criteria and none of the 
exclusion criteria mentioned above.  Details of all screened patients, whether 
recruited or not, will be entered onto the sponsor screening log.  
  
Consent 
The process of consent will be carried out in accordance with the Declaration of 
Helsinki.  All patients will be fully informed about the nature of the research 
study and the chances of being randomised to either the trial drug (aspirin) or 
placebo.  Written information will be provided to patients, who will have the 
opportunity to discuss the study with a member of the trial team prior to 
enrolment in the study.  Patients will be aware that their decision to participate 
in the study is voluntary and that they are free to withdraw consent at any time 
with no effect on the standard treatment they receive.  Written consent forms 
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will be obtained from patients willing to participate in the study and will be 
retained by the investigator.   
 
Randomisation and blinding 
Participants will be randomised on a 1:1 basis to receive either aspirin (300mg) 
or placebo, in addition to standard care.  The Research Pharmacy responsible for 
dispensing all trial medication (St George’s Hospital) will receive a 
randomisation schedule generated in advance by the IMP manufacturer, Sharp 
Clinical Services UK Ltd.  Stratification will be by ulcer size (≤5cm2 or >5cm2). 
Randomisation will be performed by the Research Pharmacy upon receipt of a 
valid prescription for a participant.  Researchers, treating staff, clinicians and 
participants will be blind to treatment allocation.  A 24-hour code breaking 
service will be provided by the Research Pharmacy in case of requirement for 
emergency unblinding and participants will receive a study-specific 24-hour 
emergency contact card. 
 
Sample size calculation  
This study aims to recruit 100 patients, which is sufficient to demonstrate 
whether there is evidence for efficacy of aspirin to treat VLUs, in line with 
previous similar trials 23,24and is also large enough to test the feasibility of study 
procedures such as recruitment. 
The primary outcome is time to healing of the reference ulcer.  Applying an 
assumed standard error for the hazard ratio (HR) of 0.105 following adjustment 
for log area and log duration of ulcer (as in VenUS IV)2 to the smaller sample size 
in this study implies that the standard error would be 0.22.  A 95% confidence 
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interval for the log hazard ratio would thus be log(HR) ± 0.435.  Hence if the 
hazard ratio for this study were the same as that suggested by previous studies 
(around 1.5), the confidence interval would be (0.97, 2.31) which just includes 
1.00.  To further increase the power an IPD meta-analysis is proposed.  As 
compliance and follow-up will be measured as part of the study there is no 
formal inflation for dropout. 
An important secondary outcome is wound area. Assuming a standard deviation 
of 1.09 following log transformation as in (VenUS I)15, two groups of 50 
participants will render 80% power to detect a difference of 0.62 on the natural 
log scale.  This corresponds to a reduction of 46% in ulcer area at follow-up.  In 
the current study, there will be multiple measurements of wound area and so 
smaller differences should be detectable. 
 
Primary outcome  
The primary outcome is time to ulcer healing, which will be defined as 
‘completed epithelial healing in the absence of scab (eschar) with no dressing 
required’.  This will take the form of survival time data for analysis.  Time to 
healing will be measured in days from the date of randomisation until the first 
date that healing is recorded.  If healing occurs before the end of the study, the 
participant will be followed for a further two weeks to confirm healing, in 
accordance with the FDA and EWMA guidelines 35.  A digital photograph of the 
area will be taken at this point to confirm healing.  For patients who have not 
healed, time from date of randomisation until they exit the trial, withdraw, are 
lost to follow up or die will be used in the survival analysis – whichever occurs 
first. 
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 Secondary outcomes 
Secondary outcomes are: 
 Ulcer size (area) measured in cm2 using image analysis by SigmaScan, 
Systat Software Inc, California and / or wound tracings 
 Recurrence of reference ulcer 
 Adverse events 
 Ulcer-related pain using a visual analogue scale 
 Treatment compliance (capsule counting and nurse assessment of 
compression concordance) 
 Resource use: number of wound consultations and types of dressings 
used 
 
Statistical analysis 
Analyses will be in accordance with the principles of intention to treat. Analysis 
will be conducted in Stata ® (Stata Corporation, College Station, Texas, USA) or 
similar statistical software. Statistical significance will be assessed at the two-
sided 5% level unless otherwise stated.  95% confidence intervals will be 
provided as appropriate.  Statistical analyses will be detailed in an analysis plan 
that will be independently reviewed and agreed before data are analysed. 
 
Primary outcome analyses 
Time to ulcer healing will be presented by trial arm using a Kaplan-Meier plot 
and a log-rank survival comparison will be made. The median time to healing 
will be presented overall and by trial arm with corresponding 95% CIs. The 
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primary analysis will investigate differences between trial arms in relation to 
time to ulcer healing using a Cox proportional hazards regression model. 
Adjustments will be made for log transformed area and duration of the reference 
ulcer.  The model will be tested for inclusion of shared centre frailty effects. 
 
Secondary outcome analyses 
Ulcer area will be transformed and investigated on the natural log scale through 
mixed models to see whether there are differences by trial arm.  
The proportion of patients who are found to have a recurrence within the study 
period will be reported by trial arm. Time from healing to recurrence will be 
investigated in a similar fashion to the primary outcome should numbers be 
sufficient to allow.  
Adverse events will be reported overall and by trial arm in terms of number of 
patients with at least one event and total number of events. Serious and non-
serious events will be presented separately and according to whether they are 
thought to be related, or unrelated, to treatment. Differences in total numbers of 
events by trial arm will be compared using negative binomial regression 
adjusting for size and duration of ulcer. 
Mean and median pain scores will be presented by trial arm and differences in 
pain scores between the allocated groups will be investigated using linear 
regression adjusted for baseline pain score.  
Compliance will be reported in terms of proportion of patients completing the 
course of treatment up to healing or planned trial exit and compared between 
arms using a Chi-squared test and 95% confidence intervals. 
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Resource use will be presented using summary statistics in relation to the 
number of wound consultations per week and change to compression therapy or 
primary wound dressings.  
 
Treatment period and follow-up 
After consent, participants will be screened to ensure eligibility.  Prior to 
randomisation, baseline demographic details will be collected and a clinical 
assessment of the patient and wound performed.  Following randomisation, 
participants will continue in the normal care pathway of weekly or two-weekly 
clinical assessments at community ulcer clinics, hospital outpatient clinics or 
home visits and will not be required to attend any further visits for research 
purposes.  All randomised participants will receive aspirin or placebo for 24 
weeks and will be followed up for 25 weeks following randomisation.  If the 
reference ulcer is confirmed as healed during the follow-up period, then a 
photograph will be taken and the participant will continue to take the IMP or 
placebo for 2 further weeks.  They will then be re-assessed (as per FDA and 
EWMA guidelines on wound healing)35.  If the ulcer is confirmed as healed at this 
reassessment visit, then the date of ulcer healing will be recorded as the date 
that the ulcer was first assessed as healed.  The participant will then be advised 
to stop taking the IMP or placebo.  If a new ulcer occurs on the reference leg 
before the end of the study, then participants will be asked to inform the study 
team.  
If the ulcer is assessed as ‘not healed’, then the participant will continue in the 
trial until the minimum period of follow up (25 weeks) has elapsed providing 
confirmed healing does not occur before the end of the follow up period.  Both of 
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these time-points (first healing judgement and confirmation of ulcer healing) will 
be recorded. 
Participants will also be asked to provide a pain score using a visual analogue 
scale at baseline and 4-6 weeks after first dose of IMP.  Weekly (or two-weekly, if 
that is the participant’s usual interval of care) assessments will include: healing 
outcomes, treatment concordance with IMP and compression bandaging, 
adverse events or side effects, change to concomitant medication, resource use 
(number of visits, types of dressings used and level of compression).  Digital 
photographs, or leg ulcer tracings, will also be taken by the treating or research 
nurse. 
 
Safety reporting 
Despite some apparent advantages of aspirin therapy in the treatment of VLUs, 
the risks associated with aspirin will carefully reported.  Safety reporting during 
this trial is paramount and will be conducted in line with HTA guidelines.  
Reportable safety events will include any of the following experienced by a 
participant during the trial:  adverse event, adverse reaction, serious adverse 
event, serious adverse reaction, suspected unexpected serious adverse reaction.  
All adverse events (AEs) will be recorded in the clinic notes, on the study case 
report form and reported to the sponsor via the sponsor AE log.   Serious adverse 
events (SAEs) and serious adverse reactions (SARs) will be notified to the 
sponsor immediately when the investigator becomes aware of the event (within 
24 hours).  The sponsor will inform the MHRA and ethics committee, where 
appropriate.  SAEs will be reported to the trial coordinator in the York Trials 
Unit via the sponsor and reviewed by the data monitoring committee. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
All patients who develop unacceptable treatment toxicity which, in the 
investigator’s opinion, is attributable to the IMP or an SAE will be withdrawn 
from the study treatment but follow-up will continue (where appropriate) to 
enable an intention to treat analysis.  The side effects associated with aspirin are 
well known to health professionals and no additional training will be required.  
These include, but are not limited to, gastrointestinal haemorrhage and 
gastrointestinal disturbance (including dyspepsia, ulceration).  
In addition, adverse events associated with leg ulceration or compression 
therapy will be recorded.  Pregnancy and breastfeeding are exclusion criteria for 
the study, however all patients of childbearing age will be advised to use barrier 
contraception during the duration of the study.   
 
Discussion / Summary 
Chronic VLUs are a common medical problem associated with considerable 
morbidity.  Current treatment (using graduated compression therapy) may not 
result in sustained wound healing, however there is inadequate evidence of 
other effective alternatives, or adjuncts, to improve outcomes.  Low-dose aspirin 
(in addition to standard compression therapy) may hasten healing, however 
current evidence supporting its use is insufficient.  This randomised trial will 
inform on whether low-dose aspirin is an effective, feasible and safe therapy for 
patients with chronic VLUs, in addition to standard compression therapy.  This 
could go some way towards addressing the significant health burden associated 
with VLUs. 
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Trial status 
At the time of submission, the trial is open to recruitment.  Collaborating centres 
include St George’s, University of London; University of York; University of 
Manchester; Bradford Teaching Hospitals NHS Foundation Trust; Harrogate & 
District NHS Foundation Trust; Hull and East Yorkshire Hospitals NHS Trust; 
University of Nottingham; Cardiff University; Newcastle University. 
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VLU: venous leg ulcer; QoL: quality of life; ABPI: ankle brachial pressure index; 
HTA: Health Technology Assessment; NHS: National Health Service; SIGN: 
Scottish Intercollegiate Guidelines Network; MHRA: Medicines and Healthcare 
products Regulatory Agency; REC: research ethics committee; IMP: 
investigational medicinal product; FDA: Food and Drug Administration; EWMA: 
European Wound Management Association. 
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Table 1: Previous randomised trials investigating aspirin in the treatment of VLU 
 
Author Year n Type of study Treatment group Control group Main results 
Layton 1994 20 Double-blind 
randomised 
Aspirin 300mg plus 
compression 
Placebo plus 
compression 
Ulcer healing within 4 months: 38% in treatment 
group vs 0% in control group (p<0.007). 
Reduction in ulcer size: 52% in treatment group 
vs 26% in placebo group (p<0.007). 
del Río 
Solá 
2012 51 Double-blind 
randomised 
Aspirin 300mg plus 
compression 
Compression only Complete healing: no difference between groups. 
Time to healing:  12 weeks in treatment group vs 
22 weeks in control group (p=0.04). 
Ulcer recurrence: no difference between groups. 
Initial area of injury was the only variable that 
influenced the rate of healing.  
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   Screening	  of	  venous	  ulcers	  in	  participating	  ulcer	  clinics-­‐	  Research	  nurses	  will	  work	  with	  community	  nurses,	  GPs	  and	  hospital	  staff	  to	  identify	  eligible	  patients,	  screen	  and	  consent	  patients	  
Informed	  consent	  to	  enter	  study	  &	  final	  eligibility	  check	  and	  prescription	  by	  a	  medically	  qualified	  person	  	  	  
Aspirin	  Placebo	  
Recruitment	  window	  6	  	  months	  Randomise	  to	  aspirin/placebo	  Alongside	  standard	  of	  care	  
Dispensed	  from	  central	  pharmacy,	  via	  courier	  to	  address	  of	  participant	  choice,	  upon	  receipt	  of	  original	  prescription	  
Research	  nurse	  or	  treating	  nurse	  will:	  1. Check	  medication	  compliance	  by	  verbal	  affirmation	  2. Administer	  weekly	  or	  bi-­‐weekly	  compressions/standard	  care	  3. Assess	  impact	  of	  treatment	  (ulcer	  size,	  healing,	  and	  pain).	  4. Monitor	  adverse	  events	  at	  treatment	  visit	  
 
Treatment	  to	  continue	  for	  up	  to	  24	  weeks	  (25	  weeks	  post-­‐randomisation).	  25	  weeks	  post-­‐randomisation	  is	  final	  follow-­‐up	  for	  all	  patients	  whose	  venous	  ulcer	  has	  either	  not	  healed	  or	  has	  been	  confirmed	  as	  healed	  earlier.	  	  
Follow-­‐up	  to	  continue	  for	  26	  weeks	  post-­‐randomisation	  for	  patients	  whose	  venous	  ulcer	  is	  suspected	  as	  healed	  in	  week	  24	  and	  27	  weeks	  for	  patients	  whose	  venous	  ulcer	  is	  suspected	  as	  healed	  in	  week	  25.	  
 
Follow-­‐up	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Screening assessment 
" Consent obtained 
" Inclusion and exclusion criteria 
checked 
" Ulcer measured to determine size!
Randomisat ion – to placebo/aspirin  
IMP to be collected by patient on next visit to clinic or posted direct to 
patient.!
Eligible patients 
 
Inel ig ible pat ients 
Anonymised screening 
data recorded 
Baseline assessments 
Clinical assessments: - Digital photo of reference ulcer and tracing.  
Record of : VAS Pain Score,  current medication, medical history, 
standard care administered (if any), demographic data, contact details 
for patient and their GP.   
Weekly  assessments fo r 25 weeks post-randomisation 
Healing outcomes – Digital photo of reference ulcer and date taken. 
Record of: Treatment concordance (including initially, date trial 
treatment commenced), adverse events/changes in medical condition, 
changes to other medication, change in type of dressings used. 
5 weeks post-randomisation 
In addition to weekly assessments, participants will be asked  about 
ulcer related pain  (VAS pain score). !
25 weeks post-randomisation: Final assessment  of patients 
whose leg ulcers have been confirmed as healed on or before week 25, 
or whose leg ulcers are not suspected as healed. 
In addition to weekly assessments, there will be a grid tracing of 
reference ulcer.  
IMP container and remaining medication returned for all trial 
participants.!
26##weeks#post+randomisation#(Only&patients&whose&leg&ulcers&were&
suspected&as&healed&in&weeks&24&and/or&25.)!
Digital!photo!taken!of!wound!area.!!
Record!of!adverse!events,!changes!to!other!medication!and!change!in!
type!of!standard!care!administered.!
(For!patients!whose!leg!ulcer!was!suspected!as!healed!in!week!24,!an!
assessment!will!be!made!of!digital!photo!to!confirm!healing.)!!
27#weeks#post+randomisation!!(Only&patients&whose&leg&ulcers&were&
suspected&as&healed&in&week&25&
Digital!photo!taken!of!wound!area.!!
Record!of!adverse!events,!changes!to!other!medication!and!change!to!
standard!care!administered/types!of!dressings!
(Assessment!of!digital!photo!to!confirm!healing).!
!
Reference ulcer judged as healed   
Participant to continue with trial 
medication 
 
1 week after  judged as healed  
Healing outcomes – Digital photo of 
reference ulcer and date taken 
Treatment concordance  
Adverse events 
Change to standard care 
administered/types of dressings. 
2 weeks after  judged as healed 
Healing outcomes – Digital photo of 
reference ulcer and date taken, and 
clinical assessment of photo. 
Treatment concordance. 
Adverse events 
Change to standard care 
administered/types of dressings 
!
Healed!!
Participant!given!a!
card!and!ask!to!notify!
the!trial!team!if!
wound!breaks!down.!
Discontinues!!trial!
medication!and!
remaining!medication!
returned!to!St!
Geroge’s!Research!
Pharmacy.!
!
Not#Healed!
Participant!
continues!with!
trial!medication!
and!continues!in!
trial!
25#weeks#post+randomisation#
Research!nurse!phones!patient!to!ask!if!ulcer!
has!reocurred!and!collect!adverse!event!data!
Additional File 3 Click here to download Figure AVURT figure 2.pdf 
  
SPIRIT checklist
Click here to access/download
Supplementary Material
SPIRIT checklist for AVURT.doc
